# Innovacell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovacell

- Industry: Biotechnology
- Headquarters: Innsbruck, Austria
- Website: www.innovacell.at
- Total disclosed funding: $15M
- Latest round: Series C (Apr 1, 2022)
- Investors on record: 4

## About

Established in 2000 and based in Innsbruck, Austria, Innovacell specializes in the treatment of urinary and fecal incontinence by cell therapies. The company's headquarter is located in Japan and has a branch in Innsbruck. The company has about 30 employees. Dr. Ekkehart Steinhuber, the CEO of the company, worked for 25 years in the pharmaceutical division of Sandoz.

The company treats urinary and fecal incontinence through regenerative medicine. The medicine includes ICES13, ICES15, and ICES16. ICES13 is used for treating stress urinary incontinence. ICES15 is used for treating urge incontinence and ICES15 is used for treating passive incontinence. The company also provides contract research and development, manufacturing and analysis services for ATMPs cell therapies.

## Funding rounds

- Series C, Apr 1, 2022, $5.7M — Yokohama Capital, Fiducia
- Series C, Dec 17, 2021, $9.7M — SBI Investment, Moroto Capital Management

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series C
- Moroto Capital Management — Series C
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series C
- Fiducia (https://capitalatlas.ai/funds/fiducia) — Series C